“Patient-centric marketing will become a fundamental pillar in the future of pharma marketing”
Sumita Mohapatro Pani, Senior General Manager, Lupin speaks to Viveka Roychowdhury on the rewriting of the pharma sales and…
Author
Will regulators catch up in 2020?
The industry will always find ways to slip through legal loopholes. Will regulators catch up in 2020?
Rationalising pharma trade margins seems next on the list
Wide price deviation between countries offering cheaper medications indicates the complexity of drug pricing strategies across…
Sustainable manufacturing practices to combat growing AMR
With antibiotic residues from effluents listed as the third highest cause of Antimicrobial Resistance (AMR), pharmaceutical…
Lupin sells stakes in Kyowa but its not a Sayonara
With headwinds in overseas markets, it is vital for pharma companies in India to grow their presence in the domestic market. But…
Sustainable manufacturing practices to combat growing AMR
With antibiotic residues from effluents listed as the third highest cause of Antimicrobial Resistance (AMR), pharmaceutical…
After sartans and ranitidine, where will NDMA show up next?
While regulators and pharma companies try to understand if it is the product or the process that is at fault in the ranitidine…
Slaying GMP non-compliance woes
Multiple warning letters call for renewed rigour to fix recurring lapses and instil a stronger quality compliance system
Heeding the clarion call for sustainability
New and existing pharma facilities will have to meet higher benchmarks to ensure that they do not pollute the environment…
Price caps are a band aid hiding larger issues
Pharma companies should not be the ones held responsible for the high prices of medicines